Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Long-Term Investments (2024 - 2025)

Dianthus Therapeutics has reported Long-Term Investments over the past 2 years, most recently at $152.9 million for Q3 2025.

  • Quarterly results put Long-Term Investments at $152.9 million for Q3 2025, up 148.65% from a year ago — trailing twelve months through Sep 2025 was $152.9 million (up 148.65% YoY), and the annual figure for FY2024 was $81.7 million, changed.
  • Long-Term Investments for Q3 2025 was $152.9 million at Dianthus Therapeutics, up from $51.7 million in the prior quarter.
  • Over the last five years, Long-Term Investments for DNTH hit a ceiling of $152.9 million in Q3 2025 and a floor of $51.7 million in Q2 2025.